Neogenomics INC 8-K Filing
Ticker: NEO · Form: 8-K · Filed: Dec 30, 2025 · CIK: 1077183
Sentiment: neutral
Filing Stats: 651 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-12-30 07:07:40
Key Financial Figures
- $0.001 — ch registered: Common Stock, par value $0.001 per share NEO The Nasdaq Stock Market L
Filing Documents
- neo-20251223.htm (8-K) — 32KB
- exhibit991-december2025app.htm (EX-99.1) — 10KB
- image_0.jpg (GRAPHIC) — 69KB
- 0001628280-25-059067.txt ( ) — 255KB
- neo-20251223.xsd (EX-101.SCH) — 2KB
- neo-20251223_lab.xml (EX-101.LAB) — 22KB
- neo-20251223_pre.xml (EX-101.PRE) — 13KB
- neo-20251223_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On December 29, 2025, the Company issued a press release regarding the foregoing, which is attached to the Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference. This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Not applicable (b) Not applicable (c) Not applicable (d) Exhibits. 99.1 Press Release of NeoGenomics, Inc. dated December 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOGENOMICS, INC. Date: December 30, 2025 By: /s/ Alicia C. Olivo Alicia C. Olivo EVP, General Counsel & Business Development and Corporate Secretary